1. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies

   • Simendra Singh
   • Alok K. Gupta

   Mini Review 05 May 2011 Pages: 1211 - 1224

   

2. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

   • Paula M. Fracasso
   • Kerry J. Williams
   • Helen Piwnica-Worms

   Original Article Open access 08 August 2010 Pages: 1225 - 1237

   

3. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

   • Athanasios G. Pallis
   • Vassilis Chandrinos
   • Vassilis Georgoulias

   Original Article 10 August 2010 Pages: 1239 - 1245

4. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)

   • Petr Sova
   • Adolf Mistr
   • Jaroslav Chládek

   Original Article 10 August 2010 Pages: 1247 - 1256

   

5. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer

   • Yen-Shen Lu
   • Dar-Ren Chen
   • Chiun-Sheng Huang

   Original Article 11 August 2010 Pages: 1257 - 1263

   

6. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

   • Ken Kato
   • Makoto Tahara
   • Taku Seriu

   Original Article 12 August 2010 Pages: 1265 - 1272

   

7. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

   • N. L. Steele
   • J. A. Plumb
   • T. R. J. Evans

   Original Article 13 August 2010 Pages: 1273 - 1279

   

8. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan

   • Jen-Shi Chen
   • Yee Chao
   • Jacqueline Whang-Peng

   Original Article 17 August 2010 Pages: 1281 - 1289

   

9. Plasma and CNS pharmacokinetics of O⁴-benzylfolic acid (O⁴BF) and metabolite in a non-human primate model

   • Meredith K. Chuk
   • Diane E. Cole
   • Elizabeth Fox

   Original Article 20 August 2010 Pages: 1291 - 1297

   

10. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance

    • Murugan Kalimutho
    • Antonella Minutolo
    • Sergio Bernardini

    Original Article 24 August 2010 Pages: 1299 - 1312

    

11. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

    • S. Aubrey Stoch
    • Cynthia Gargano
    • Howard E. Greenberg

    Original Article 24 August 2010 Pages: 1313 - 1321

    

12. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

    • Junshik Hong
    • Sae-Won Han
    • Tae-You Kim

    Original Article 24 August 2010 Pages: 1323 - 1331

    

13. Detection of doxorubicin hydrochloride accumulation in the rat brain after morphine treatment by mass spectrometry

    • Iacopo Sardi
    • Giancarlo la Marca
    • Maurizio Aricò

    Original Article 25 August 2010 Pages: 1333 - 1340

    

14. Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator

    • Linda Rausch
    • Carol Green
    • Jon Mirsalis

    Original Article 25 August 2010 Pages: 1341 - 1352

    

15. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

    • Johanna Hilli
    • Liisa Sailas
    • Kari Laine

    Original Article 27 August 2010 Pages: 1353 - 1362

    

16. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

    • Chikara Kunisaki
    • Masazumi Takahashi
    • Itaru Endo

    Original Article 28 August 2010 Pages: 1363 - 1368

    

17. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma

    • Changxia Shao
    • Chuanwen Lu
    • Weimin Gao

    Original Article 28 August 2010 Pages: 1369 - 1380

    

18. Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation

    • Heiko Bugger
    • Cinthia Guzman
    • Raymond R. Russell III

    Original Article 31 August 2010 Pages: 1381 - 1388

    

19. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

    • Chi-Hui Tang
    • Christi Parham
    • Neela Patel

    Original Article Open access 31 August 2010 Pages: 1389 - 1400

    

20. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor

    • Edi Levi
    • Liyue Zhang
    • Arun K. Rishi

    Original Article 31 August 2010 Pages: 1401 - 1413

    

21. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models

    • Idoia Gamez
    • Robert P. Ryan
    • Beth A. Hollister

    Original Article 31 August 2010 Pages: 1415 - 1422

    

22. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer

    • D. Takahari
    • T. Hamaguchi
    • M. Sasako

    Original Article 01 September 2010 Pages: 1423 - 1428

23. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer

    • Masashi Kanai
    • Kenichi Yoshimura
    • Etsuro Hatano

    Original Article 02 September 2010 Pages: 1429 - 1434

24. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer

    • Yoon-Koo Kang
    • Min-Hee Ryu
    • Tae Won Kim

    Original Article 02 September 2010 Pages: 1435 - 1443

    

25. Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model

    • Di Xiang
    • Yiping Guo
    • Wei Han

    Original Article 03 September 2010 Pages: 1445 - 1453

    

26. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

    • Carlo Buonerba
    • Piera Federico
    • Giuseppe Di Lorenzo

    Clinical Trial Report 02 March 2011 Pages: 1455 - 1461

    

27. Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

    • Carlo Buonerba
    • Piera Federico
    • Giuseppe Di Lorenzo

    Erratum 30 March 2011 Pages: 1463 - 1463

28. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

    • Takeshi Masuda
    • Noboru Hattori
    • Nobuoki Kohno

    Short Communication 28 January 2011 Pages: 1465 - 1469

29. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

    • Sin-Chi Chew
    • Onkar Singh
    • Balram Chowbay

    Short Communication 06 April 2011 Pages: 1471 - 1478

    

30. Estimating the correct way of calculating the carboplatin dose

    • Jesús F. Sierra-Sánchez
    • Triana González-Carrascosa

    Letter to the Editor 20 March 2011 Pages: 1479 - 1480

31. Prospectives and limitations by a novel algorithm

    • Karin Holweger
    • Hans-Peter Lipp

    Reply to the Letter 20 March 2011 Pages: 1481 - 1482